A Pilot Study of Priming With Granulocyte Macrophage Colony-Stimulating Factor Plus All-trans Retinoic Acid Combined With Remission Induction Chemotherapy in Patients With Acute Myeloid Leukemia

• DOI: 10.1097/coc.0b013e3181844d2e
• Publication Date: 2009-05-21T09:48:55Z
• Authors: Ho-Jin Shin; Joo Seop Chung; Young Jin Choi; Goon Jae Cho
• Keywords: Regimen; Induction chemotherapy; Priming (agriculture); Acute myeloblastic leukemia

Priming with granulocyte macrophage colony-stimulating factor (GM-CSF) plus all-trans retinoic acid (ATRA) during induction chemotherapy may enhance response rates and survival in patients acute myeloid leukemia (AML) due to the differentiation of human myeloblastic cells into granulocytes.GM-CSF was administered ATRA ingested orally on days 1 14. Patients undergoing a regimen GM-CSF were evaluated as compared historical control group subjects.For enrolled this study, complete remission incomplete platelet recovery rate 61.5% 41.4% for subjects. The relapse 38.5% 44.8% study subjects, respectively. Two-year probabilities 45.5% (study group) 47.4% (control disease-free 36.2% overall survival. most frequent side effects included fever, headache, skin lesions pruritus dyspnea pulmonary congestion, similar syndrome.Priming anthracycline-based is feasible terms rate, but toxicity significant.